Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.

Original languageEnglish
Pages (from-to)132-136
Number of pages5
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume67
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Practice Management
Chronic Hepatitis C
Hepatitis C
Practice Guidelines
Antiviral Agents
Genotype
Liver
Evidence-Based Medicine
Expert Testimony
Therapeutics
Korea
Drug Interactions
Interferons
Guidelines
Pharmaceutical Preparations

Keywords

  • Antiviral agents
  • Chronic hepatitis C
  • Evidence-based medicine
  • Genotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9d1fa2efcc1a429eaa212671a4dcb48c,
title = "Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3",
abstract = "Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90{\%} with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.",
keywords = "Antiviral agents, Chronic hepatitis C, Evidence-based medicine, Genotype",
author = "Jung, {Young Kul}",
year = "2016",
month = "3",
day = "1",
doi = "10.4166/kjg.2016.67.3.132",
language = "English",
volume = "67",
pages = "132--136",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "3",

}

TY - JOUR

T1 - Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3

AU - Jung, Young Kul

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.

AB - Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.

KW - Antiviral agents

KW - Chronic hepatitis C

KW - Evidence-based medicine

KW - Genotype

UR - http://www.scopus.com/inward/record.url?scp=85015353183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015353183&partnerID=8YFLogxK

U2 - 10.4166/kjg.2016.67.3.132

DO - 10.4166/kjg.2016.67.3.132

M3 - Review article

C2 - 26996182

AN - SCOPUS:85015353183

VL - 67

SP - 132

EP - 136

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 3

ER -